Stockscreener 앱 받기
0.9389
2.20%
-0.0211
시간 외 거래:
.93
-0.0089
-0.95%
전일 마감가:
$0.96
열려 있는:
$0.9145
하루 거래량:
20,331
Relative Volume:
0.50
시가총액:
$51.34M
수익:
$117.93M
순이익/손실:
$5.00M
주가수익비율:
7.1454
EPS:
0.1314
순현금흐름:
$-12.91M
1주 성능:
+10.45%
1개월 성능:
+14.50%
6개월 성능:
-33.88%
1년 성능:
-37.41%
1일 변동 폭
$0.91
$0.95
1주일 범위
$0.8657
$0.9999
52주 변동 폭
$0.68
$1.7698
Intercure Ltd Stock (INCR) Company Profile
Compare INCR vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INCR
Intercure Ltd
|
0.9389 | 52.22M | 117.93M | 5.00M | -12.91M | 0.1314 |
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.87 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.56 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.26 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
551.47 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Intercure Ltd Stock (INCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-05-18 | 업그레이드 | Canaccord Genuity | Speculative Buy → Buy |
Intercure Ltd 주식(INCR)의 최신 뉴스
InterCure Advances Global Push With Botanico Acquisition Tranche and U.S. Strategy Review - TipRanks
InterCure completes first tranche of Botanico acquisition By Investing.com - Investing.com Canada
InterCure Ltd. Completes First Tranche of Botanico Acquisition to Enhance International Medical Cannabis Platform - Quiver Quantitative
InterCure (NASDAQ: INCR) advances Botanico deal and eyes U.S. medical cannabis - Stock Titan
U.S. cannabis shift prompts InterCure rethink and new launches in Germany - Stock Titan
Intercure Ltd. (INCR) Holds Near Support as Modest Gains Signal Stabilization AttemptRevenue Weighted - newsline.com
INCR Q2 2023 Earnings: EPS Surpasses Estimates by 28.7%, Driving Stock HigherPositive Surprise Momentum - newsline.com
INCR Q2 2023 Earnings: EPS Surges Past Estimates, Stock Declines Amid Broader Market HeadwindsAnalyst Coverage Count - newsline.com
Intercure Ltd. (INCR) Q2 2023 Earnings: EPS Beat Drives 12.15% Stock SurgeEnergy Earnings Report - newsline.com
INCR Q2 2023 Earnings: EPS Surpasses Estimates by 28.68%Debt Analysis Report - The Legal Advocate
Intercure Ltd. (INCR) Q2 2023 Earnings: EPS Surges Past Estimates, Stock RalliesSurprise Factor Analysis - The Legal Advocate
Intercure Ltd. Shares Surge Over 15% as Cannabis Sector Sees Renewed InterestThrowback Trade - newsline.com
INCR Q2 2023 Earnings: EPS Surges Past Estimates as Profitability StrengthensProfit Warning Alert - The Legal Advocate
Intercure Ltd. (INCR) Rallies 5.57% as It Approaches Key Resistance LevelRSI Oversold Picks - The Legal Advocate
INCR Q2 2023 Earnings: Strong EPS Beat Highlights Operational EfficiencyEarnings Analysis - thelegaladvocate.com
Intercure Ltd. (INCR) Rallies 4.8%: Testing Key Resistance at $0.97Volatility Breakout Picks - newsline.com
INCR Q2 2023 Earnings: EPS Beat Surprises by 28.7% Despite Revenue UncertaintySlow Growth Warning - newsline.com
INCR Q2 2023 Earnings: EPS Surges Past Estimates as Company Delivers Strong Operational ResultsEarnings Trend Analysis - Newser
INCR Q2 2023 Earnings: EPS Surprises 28.68% Above Estimates Despite Negative Stock ReactionSocial Signal Watchlist - Newser
INCR (Intercure) beats Q2 estimates by 28% but shares fall 4% despite earnings surprise.AI Stock Signals - newser.com
How Intercure (INCR) performance reflects its true potential (Smart Money Flows) 2026-05-05Real Trader Insights - newser.com
InterCure Posts 2025 Revenue Growth, Positive Cash Flow as Recovery and Expansion Accelerate - The Globe and Mail
InterCure (NASDAQ: INCR) grows 2025 revenue to NIS 270M with positive cash flow - Stock Titan
InterCure Ltd. Reports NIS 270 Million Revenue and Positive Cash Flow for 2025 Amid Recovery Efforts - Quiver Quantitative
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow - Weekly Voice
Intercure LTD (INCR) Releases Q4 2025 Earnings: Revenue Up 43.8% but Company Remains Unprofitable - Quiver Quantitative
InterCure (INCR) 2025 20-F outlines licensing, war and market risks - Stock Titan
InterCure Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Intercure (INCR) director discloses shares and stock options - Stock Titan
Intercure (INCR) director reports 15,000 share options at $3.10 strike - Stock Titan
Intercure (INCR) CEO details major share, warrant and option holdings - Stock Titan
David Salton Net Worth (2026) - GuruFocus
Amos Cohen Net Worth (2026) - GuruFocus
Gideon Hirschfeld Net Worth (2026) - GuruFocus
Intercure (INCR) CFO discloses option grants and share stake - Stock Titan
Intercure (INCR) director Gideon Hirschfeld reports existing stock option grants - Stock Titan
Intercure (INCR) director David Salton reports option positions in Form 3 - Stock Titan
Intercure (INCR) Stock: Portfolio Addition? (Selling Pressure) 2026-04-15BPI Bull Confirmed - thelegaladvocate.com
Investment Report: Whats the fair value of InterCure Ltd stockRisk Management & Consistent Growth Stock Picks - baoquankhu1.vn
Aug Levels: Is InterCure Ltd being accumulated by smart moneyExit Point & Weekly Breakout Stock Alerts - baoquankhu1.vn
Analyst Calls: How volatile is InterCure Ltd stock2026 Risk Factors & Short-Term High Return Ideas - baoquankhu1.vn
INCR PE Ratio & Valuation, Is INCR Overvalued - Intellectia AI
INCR Price Today: Intercure Ltd. Stock Price, Quote & Chart - MEXC Exchange
Stock Report: Is InterCure Ltd a potential multi bagger2026 Spike Watch & Safe Capital Preservation Plans - baoquankhu1.vn
Aug Update: Should I invest in InterCure Ltd before earnings2026 Top Decliners & Fast Moving Trade Plans - baoquankhu1.vn
INCR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Highs Report: Why is InterCure Ltd stock going up2026 Performance Recap & Weekly Setup with High ROI Potential - baoquankhu1.vn
Stock Analysis: Is InterCure Ltd being accumulated by smart money2026 Macro Impact & Weekly Market Pulse Updates - baoquankhu1.vn
Aug Highlights: What are analysts price targets for InterCure LtdTreasury Yields & Accurate Intraday Trade Tips - baoquankhu1.vn
Intercure (INCR) Stock Analysis Report | Financials & Insights - Benzinga Japan
Market Fear: Is HCAT stock forming a triangle patternProduct Launch & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Intercure Ltd (INCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.95%
1.13%
자본화:
|
볼륨(24시간):